Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Staar Surgical ( (STAA) ) is now available.
STAAR Surgical announced it will release its financial results for Q4 and fiscal year 2024 on February 19, 2025, after market close. The company reported double-digit global sales growth for its EVO ICL™ technology, except in China due to economic conditions affecting consumer confidence. The forthcoming Chinese New Year and recent stimulus are expected to impact STAAR’s 2025 outlook, which will be discussed in their earnings call.
More about Staar Surgical
STAAR Surgical Company, headquartered in Lake Forest, CA, specializes in ophthalmic surgery, designing, developing, manufacturing, and marketing implantable lenses for vision correction. The company’s flagship product is the Implantable Collamer® Lens (ICL), including the EVO ICL™ line, which aims to reduce reliance on glasses or contacts. STAAR operates globally, with over 3 million ICLs sold across more than 75 countries, and maintains manufacturing facilities in California and Switzerland.
YTD Price Performance: -4.56%
Average Trading Volume: 626,911
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.13B
For detailed information about STAA stock, go to TipRanks’ Stock Analysis page.
